[{"orgOrder":0,"company":"Nanomerics","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"AnQlar","moa":"ACE","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Nanomerics \/ Virpax","highestDevelopmentStatusID":"5","companyTruncated":"Nanomerics \/ Virpax"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"OC134","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Nanomerics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Not Applicable"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Not Applicable","leadProduct":"OC134","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Nanomerics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Not Applicable"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"OC134","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Nanomerics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Quotient Sciences"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Drops","sponsorNew":"Nanomerics \/ Nanomerics","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Nanomerics"}]